---
title: Feasibility, Safety and Efficacy of Remote Ischemic Preconditioning for Symptomatic Intracranial Arterial Stenosis in Octogenarians
nct_id: NCT01570231
overall_status: COMPLETED
phase: PHASE1
sponsor: Ji Xunming
study_type: INTERVENTIONAL
primary_condition: Bilateral Limb Ischemic Preconditioning
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01570231.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01570231"
ct_last_update_post_date: 2012-07-27
last_seen_at: "2026-05-12T07:10:38.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Feasibility, Safety and Efficacy of Remote Ischemic Preconditioning for Symptomatic Intracranial Arterial Stenosis in Octogenarians

**Official Title:** Feasibility, Safety and Efficacy of RIPC for Symptomatic Intracranial Arterial Stenosis in Octogenarians

**NCT ID:** [NCT01570231](https://clinicaltrials.gov/study/NCT01570231)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 58
- **Lead Sponsor:** Ji Xunming
- **Collaborators:** Capital Medical University
- **Conditions:** Bilateral Limb Ischemic Preconditioning, Intracranial Arterial Stenosis
- **Start Date:** 2008-01
- **Completion Date:** 2010-12
- **CT.gov Last Update:** 2012-07-27

## Brief Summary

Making a limb transiently ischemic induces ischemic tolerance in distant organs such as the heart. This study aims to evaluate the feasibility, safety and initial efficacy of using briefly repetitive bilateral limb ischemic preconditioning (BLIPC) to protect the brain in octogenarians with symptomatic intracranial arterial stenosis.

## Eligibility

- **Minimum age:** 80 Years
- **Maximum age:** 95 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. age between 80 to 95 years old
2. Trial of Org 10172 in Acute Stroke Treatment-1 (TOAST-1) subtype
3. National Institutes of Health Stroke Scale (NIHSS) score 0-15, and Modified Rankin Scale (mRS) score 0-4
4. ABCD2 score between 6 to 7
5. stable vital signs, normal hepatic and renal functions
6. no hemorrhagic tendencies

Exclusion Criteria:

1. within 72 hrs of intra-artery or intravenous thrombolysis
2. intracranial hemorrhage or large area of cerebral infarction (more than 1/3 middle cerebral artery perfusion territory)
3. any soft tissue, orthopedic, or vascular injury, wounds or fractures in extremities which may pose a contraindication for application of the preconditioning cuffs
4. acute myocardial infarction
5. systolic blood pressure more than 200 mmHg after drug control
6. peripheral blood vessel disease
7. hematologic disease
8. severe hepatic and renal dysfunction
9. severe or unstable concomitant disease
10. cannot tolerate BLIPC or without informed consent
```

## Arms

- **bilateral limb ischemic preconditioning (BLIPC)** (EXPERIMENTAL) — 5 minutes bilateral limb ischemic preconditioning treatment with an inflating tourniquets to 200 mmHg
- **Control group** (NO_INTERVENTION) — underwent equivalent medical treatments only

## Interventions

- **bilateral limb ischemic preconditioning (Doctormate, IPC-906X)** (DEVICE) — Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X, produced by Beijing Renqiao Institute of Neuroscience)five cycles of 5 minutes bilateral upper limb ischemia-reperfusion performed by inflating tourniquets to 200 mmHg, twice daily for 180 consecutive days, along with conventional medical treatment.

## Primary Outcomes

- **objective signs of tissue or neurovascular injury** _(time frame: 180 days after treatment)_ — objective signs of tissue or neurovascular injury felt to be due to cuff inflation, which was based on the judgment of the observers (blinded to study protocol) precluded continuation. Inspection included palpation of distal radial pulses, visual inspection (for local edema, redness, skin breakdown), and palpation for tenderness
- **levels of plasma biomarkers** _(time frame: 180-day)_ — levels of plasma myoglobin at baseline and at the 1st, 15th and 30th day during BLIPC treatment were monitored

## Locations (1)

- Capital Medical University, Beijing, China

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.capital medical university|beijing||china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01570231.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01570231*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*